Business Description
Cellectar Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US15117F5008
Description
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 66.79 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 25.4 | |||||
| 3-Year EPS without NRI Growth Rate | 25.4 | |||||
| 3-Year FCF Growth Rate | 27.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 49.96 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 5.84 | |||||
| 9-Day RSI | 11.57 | |||||
| 14-Day RSI | 17.55 | |||||
| 6-1 Month Momentum % | -35.14 | |||||
| 12-1 Month Momentum % | -18.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.77 | |||||
| Quick Ratio | 1.77 | |||||
| Cash Ratio | 1.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -65.9 | |||||
| Shareholder Yield % | 0.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -994.19 | |||||
| ROA % | -174.94 | |||||
| ROIC % | -403.15 | |||||
| ROC (Joel Greenblatt) % | -3519.45 | |||||
| ROCE % | -519.62 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 33.68 | |||||
| Price-to-Tangible-Book | 29.5 | |||||
| EV-to-EBIT | -0.63 | |||||
| EV-to-EBITDA | -0.64 | |||||
| EV-to-Forward-Revenue | 1.51 | |||||
| EV-to-FCF | -0.71 | |||||
| Price-to-Net-Cash | 4.21 | |||||
| Earnings Yield (Greenblatt) % | -158.73 | |||||
| FCF Yield % | -87.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cellectar Biosciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.74 | ||
| Beta | -0.47 | ||
| Volatility % | 76.15 | ||
| 14-Day RSI | 17.55 | ||
| 14-Day ATR (€) | 0.054027 | ||
| 20-Day SMA (€) | 1.477 | ||
| 12-1 Month Momentum % | -18.64 | ||
| 52-Week Range (€) | 1.18 - 3.82 | ||
| Shares Outstanding (Mil) | 41.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cellectar Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cellectar Biosciences Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cellectar Biosciences Inc Frequently Asked Questions
What is Cellectar Biosciences Inc(STU:NV4)'s stock price today?
The current price of STU:NV4 is €1.18. The 52 week high of STU:NV4 is €3.82 and 52 week low is €1.18.
When is next earnings date of Cellectar Biosciences Inc(STU:NV4)?
The next earnings date of Cellectar Biosciences Inc(STU:NV4) is 2025-03-27 Est..
Does Cellectar Biosciences Inc(STU:NV4) pay dividends? If so, how much?
Cellectar Biosciences Inc(STU:NV4) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers